Class A Common Stock, $0.0001 par value per share
- Symbol
- NUVB
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Nuvation Bio Inc.
NUVBNYSEEQUITYCurrent
Results of Operations and Financial Condition
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION On November 4, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.…
Press release in this filing
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update →Company context
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Current securities
Registered securities in this filing
Nuvation Bio Inc. · 8-K · Filed 2026-11-04
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 4, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both first-line and all lines of therapy combined, based on IQVIA claims data FDA approved a supplemental New Drug Application (sNDA) for IBTROZI, updating label to reflect median duration of response of 49.7 months in TKI-naïve ROS1+ NSCLC patients in TRUST-I FDA granted Fast Track Designation to safusidenib for the treatment of IDH1-mutant glioma Cash, cash equivalents, and marketable securities of $663.4 million as of September 30, 2026 Company to host a conference call today at 4:30 p.m. ET NEW YORK, November 4, 2026 - Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “Just over one year after launch, …
Open exhibit ↗